Plus, at least 20 are next-generation versions of kinase pathways that have already been validated, including VEGFR and BTK. But the race is on to develop novel kinase inhibitors, too.

“If our future research can explain how an activated spleen tyrosine kinase pathway leads to increased risk of side effects from immunotherapy, then it could also potentially help us to design ...

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

BTK, a cytoplasmic tyrosine kinase, is expressed in B cells and in hematopoietic lineages including monocytes, macrophages, microglia, mast cells, and neutrophils. 44,58 The BTK pathway is ...

Tyrosine Kinase Inhibitors: Transforming nAMD Treatment This activity is supported by an educational grant from EyePoint Pharmaceuticals, Inc. 0.75 CME ... TKIs target intracellular pathways, ...